Arcadia Biosciences Inc (RKDA) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Arcadia Biosciences Inc stock $0.21, price $0.16, upside +32.4%, quality 51 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients.
Show moreShow less
Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
Stock analysis
Arcadia Biosciences Inc (RKDA) currently trades at $0.1579, while our model-based Fair Value estimate is $0.2090, implying the stock looks roughly 24.4% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.1376 (bear) to $0.2613 (bull), the price of $0.1579 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Arcadia Biosciences Inc reported revenue of $4.9M in FY2025 versus $6.8M in FY2021, a compound −8.0%/yr. Reported net income was −$2.3M in FY2025.
Key figures
Market cap $411K Micro · P/S ratio 0.09 · EPS (TTM) $−4.55 · Net margin −48.1% · Return on equity −431% · Return on assets (EBIT) −68.0% · Operating margin −34.4% · Revenue (TTM) $4.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 96% below its 52-week high and 9% above its 52-week low.
For context, the median of 10 Consumer Defensive peers we cover trades at −21% fair-value upside, at 32%, RKDA screens cheaper than that median.
Fair Value models
Bear$0.1376Fair Value $0.2090Bull$0.2613
Price $0.1579 · Upside +32.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.6%
Start year 2020 (pandemic). Over 10 years: −1.1% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−159.0% (2020) → −205.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Arcadia Biosciences Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 635 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside+22.6% · Above median
Profitability
Return on assets−35.7% · Bottom 25%
Net margin (12 months)−48.1% · Bottom 25%
Operating margin (12 months)−34.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−0.8% · Below median
Balance sheet
Debt / equity0.51× · Highest 25%
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Arcadia Biosciences Inc (RKDA) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of $0.2090 versus a price of $0.1579, about +32% upside (undervalued).
What is the fair value of RKDA?
Our model-based fair value for Arcadia Biosciences Inc is $0.2090 (as of Oct 30, 2026), built from audited fundamentals. The current price: $0.1579.
What is the quality score of RKDA?
Arcadia Biosciences Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arcadia Biosciences Inc (RKDA)?
Our model-based price target is the fair value of $0.2090 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario $0.1376, optimistic scenario $0.2613. It is a calculation from audited fundamentals, not an analyst target.
What is the Arcadia Biosciences Inc stock forecast for 2026?
Our models put fair value at $0.2090, about +32% upside versus a price of $0.1579 (undervalued). Cautious scenario $0.1376, optimistic scenario $0.2613. The calculation is refreshed regularly with new filings.
What is the revenue of Arcadia Biosciences Inc (RKDA)?
Arcadia Biosciences Inc reported trailing-twelve-month revenue of about $4.7M (latest available figure, as of Oct 30, 2026).
What is the intrinsic value of Arcadia Biosciences Inc (RKDA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arcadia Biosciences Inc it is $0.2090 per share (as of Oct 30, 2026), against a price of $0.1579. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Arcadia Biosciences Inc stock overvalued or undervalued in 2026?
As of Oct 30, 2026, RKDA trades below its calculated fair value: price $0.1579, fair value $0.2090, a gap of about +32% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RKDA?
No. The price is what the market pays today ($0.1579); the fair value is what the company's own numbers justify ($0.2090). For Arcadia Biosciences Inc the two are $0.0511 per share apart. That gap is exactly why we show both numbers side by side.
How much is Arcadia Biosciences Inc worth?
The market values Arcadia Biosciences Inc at about $411K (market capitalisation, as of Oct 30, 2026). Per share that is $0.1579; our models calculate a fair value of $0.2090 per share.
What do the bullish and bearish scenarios say about RKDA?
Our models span a range for Arcadia Biosciences Inc: cautious scenario $0.1376, base $0.2090, optimistic $0.2613 per share (as of Oct 30, 2026, price $0.1579). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Arcadia Biosciences Inc (RKDA)?
Balance-sheet figures for Arcadia Biosciences Inc (as of Oct 30, 2026): return on equity −430.9%, debt of 0.51 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is RKDA from its 52-week high?
Arcadia Biosciences Inc trades at $0.1579, about 96% below its 52-week high of $3.90 and 9% above the low of $0.1450 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2090 is for.
Which stocks are comparable to Arcadia Biosciences Inc?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arcadia Biosciences Inc stock attractive at the current price?
The data as of Oct 30, 2026: price $0.1579, calculated fair value $0.2090 (+32%), Quality Score 51/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RKDA calculated?
We run Arcadia Biosciences Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2090, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Arcadia Biosciences Inc currently trades 24 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Arcadia Biosciences Inc (RKDA)?
The closing price on Oct 30, 2026 was $0.1579. Our model-based fair value is $0.2090, about +32% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Arcadia Biosciences Inc right now?
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($0.1376 to $0.2613) leaves room in how you read the outcome.
Key figures of Arcadia Biosciences Inc
How large is the market capitalisation of Arcadia Biosciences Inc (RKDA)?
The market capitalisation of Arcadia Biosciences Inc is $411K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arcadia Biosciences Inc (RKDA)?
The price-to-sales ratio of Arcadia Biosciences Inc is 0.09 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arcadia Biosciences Inc (RKDA)?
Earnings per share at Arcadia Biosciences Inc are $−4.55. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Arcadia Biosciences Inc (RKDA)?
The net margin of Arcadia Biosciences Inc is −48.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arcadia Biosciences Inc (RKDA)?
The return on equity (ROE) of Arcadia Biosciences Inc is −431% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arcadia Biosciences Inc (RKDA)?
On an EBIT basis the return on assets of Arcadia Biosciences Inc is −68.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arcadia Biosciences Inc (RKDA)?
The operating margin of Arcadia Biosciences Inc is −34.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arcadia Biosciences Inc (RKDA)?
Revenue at Arcadia Biosciences Inc is growing −0.8% versus a year earlier (3y avg −13.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Arcadia Biosciences Inc (RKDA)?
Earnings per share at Arcadia Biosciences Inc are growing +28.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Arcadia Biosciences Inc (RKDA) generate?
The free cash flow of Arcadia Biosciences Inc is −$4.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Arcadia Biosciences Inc (RKDA) hold?
Arcadia Biosciences Inc holds more cash than debt, $259K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Arcadia Biosciences Inc in the live analysis
One click puts Arcadia Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 30, 2026